Mangrove Partners Mereo Biopharma Group PLC Transaction History
Mangrove Partners
- $936 Million
- Q1 2024
A detailed history of Mangrove Partners transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Mangrove Partners holds 8,752,893 shares of MREO stock, worth $31.5 Million. This represents 3.09% of its overall portfolio holdings.
Number of Shares
8,752,893
Previous 8,752,893
-0.0%
Holding current value
$31.5 Million
Previous $20.2 Million
42.86%
% of portfolio
3.09%
Previous 2.02%
Shares
2 transactions
Others Institutions Holding MREO
# of Institutions
88Shares Held
85.6MCall Options Held
182KPut Options Held
249K-
Rubric Capital Management LP New York, NY13.6MShares$48.8 Million1.52% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.33MShares$33.6 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD8.14MShares$29.3 Million0.7% of portfolio
-
683 Capital Management, LLC New York, NY5.75MShares$20.7 Million1.62% of portfolio
-
Janus Henderson Group PLC London, X05.12MShares$18.4 Million0.01% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $450M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...